UA93181C2 - СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ - Google Patents

СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ

Info

Publication number
UA93181C2
UA93181C2 UAA200609258A UAA200609258A UA93181C2 UA 93181 C2 UA93181 C2 UA 93181C2 UA A200609258 A UAA200609258 A UA A200609258A UA A200609258 A UAA200609258 A UA A200609258A UA 93181 C2 UA93181 C2 UA 93181C2
Authority
UA
Ukraine
Prior art keywords
antibody
preparing
cells
peptide
endogenously
Prior art date
Application number
UAA200609258A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Рональд Брендли Дематтос
Ума Кучиботла
Хсю-Чунг Янг
Дон Б. Макклюр
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA93181C2 publication Critical patent/UA93181C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
UAA200609258A 2004-02-23 2005-02-17 СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ UA93181C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23

Publications (1)

Publication Number Publication Date
UA93181C2 true UA93181C2 (ru) 2011-01-25

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200609258A UA93181C2 (ru) 2004-02-23 2005-02-17 СПОСОБ ПОЛУЧЕНИЯ АНТИТЕЛА K Ab ПЕПТИДУ

Country Status (20)

Country Link
US (1) US20070190046A1 (enExample)
EP (1) EP1720909B1 (enExample)
JP (1) JP4851348B2 (enExample)
KR (2) KR100889430B1 (enExample)
CN (1) CN1922209B (enExample)
AT (1) ATE534667T1 (enExample)
AU (1) AU2005217596B2 (enExample)
BR (1) BRPI0507856A (enExample)
CA (1) CA2556436C (enExample)
CY (1) CY1112162T1 (enExample)
DK (1) DK1720909T3 (enExample)
EA (1) EA009872B1 (enExample)
ES (1) ES2375627T3 (enExample)
IL (1) IL177611A (enExample)
NO (1) NO20064239L (enExample)
PL (1) PL1720909T3 (enExample)
PT (1) PT1720909E (enExample)
SI (1) SI1720909T1 (enExample)
UA (1) UA93181C2 (enExample)
WO (1) WO2005082939A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
NZ568012A (en) 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2376120A2 (en) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
BR112012009997A2 (pt) 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
SI3339323T1 (sl) * 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
JP2019524788A (ja) * 2016-08-11 2019-09-05 イーライ リリー アンド カンパニー アミノチアジンおよびｂａｃｅ１阻害剤としてのそれらの使用
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002258808A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies

Also Published As

Publication number Publication date
EA200601545A1 (ru) 2007-02-27
WO2005082939A3 (en) 2005-10-27
CA2556436A1 (en) 2005-09-09
ES2375627T3 (es) 2012-03-02
BRPI0507856A (pt) 2007-07-10
WO2005082939A2 (en) 2005-09-09
AU2005217596B2 (en) 2012-01-19
IL177611A0 (en) 2006-12-10
AU2005217596A1 (en) 2005-09-09
KR100889430B1 (ko) 2009-03-23
EP1720909A2 (en) 2006-11-15
DK1720909T3 (da) 2012-01-30
PL1720909T3 (pl) 2012-04-30
CY1112162T1 (el) 2015-12-09
CA2556436C (en) 2014-04-01
KR20090005410A (ko) 2009-01-13
JP4851348B2 (ja) 2012-01-11
CN1922209B (zh) 2012-09-05
CN1922209A (zh) 2007-02-28
EP1720909B1 (en) 2011-11-23
SI1720909T1 (sl) 2012-01-31
KR20060126785A (ko) 2006-12-08
NO20064239L (no) 2006-11-20
ATE534667T1 (de) 2011-12-15
US20070190046A1 (en) 2007-08-16
IL177611A (en) 2013-05-30
PT1720909E (pt) 2011-12-23
JP2008500279A (ja) 2008-01-10
EA009872B1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
TW200801262A (en) Method for purifying silicon
SG149061A1 (en) Definitive endoderm
MX348414B (es) Poblaciones de celula madre de la placenta.
MX2009002991A (es) Indicador de esterilizacion.
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
TW200631917A (en) Synthetic aggregates comprising sewage sludge and other waste materials and methods for producing such aggregates
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
WO2007134294A3 (en) Novel chlorella species and uses therefor
TW200700092A (en) Tigecycline compositions and methods of preparation
WO2008009639A3 (en) New indications for direct thrombin inhibitors
PL1974017T3 (pl) Środki i sposoby do wpływania na stabilność komórek wytwarzających przeciwciała
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
AU2019268061A1 (en) Placental stem cell populations
NO20075094L (no) Fremstilling av ammoniumdinitroamid(ADN)krystaller, krystallene og de energirike sammensetninger som inneholder disse krystallene
MX2009006097A (es) Sistema y metodo para la formacion de un cristal.
ATE531805T1 (de) Transgene ananaspflanzen mit modifiziertem carotinoidgehalt und verfahren zu ihrer herstellung
DE502005004058D1 (de) Verfahren zur deacylierung von lipopeptiden
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
CY1112973T1 (el) Περαιτερω κρυσταλλικες μορφες ροσταφουροξινης
PH12021550950A1 (en) Method for culturing cord blood-derived natural killer cells using transformed t cells
BRPI0509302A (pt) método de purificação de oócitos de uma composição que compreende material fecal
DK1651754T3 (da) Myelomcellekultur i transferrinfrit medium med lavt jernindhold
WO2008052803A3 (en) Zeolite crystals with biological material
AU2003209737A1 (en) Methods for increasing the oil content in plants by reducing the content of one or more storage proteins
IN2010CN01933A (enExample)